Werkgroep Cardiologische centra Nederland

SURPASS–CVOT (Recruiting)

Double-blind study comparing Tirzepatide (up to 15mg) to placebo on Major Cardiovascular events, when added to glucose-lowering regimen and other standard of care (e.g. beta blockers, aspirin, ace inhibitors, statins), in patients with T2DM and with established CV disease
Medicine
Tirzepatide
Population
Diabetes mellitus
Phase
III
Starting year
2019
More information
Clinicaltrials.gov

Director of Study

dr. F.J.F. Broeyer (Cardioloog)
Amstelveen, Ziekenhuis Amstelland